Abstract:Mutations in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD) and are the greatest known genetic risk factors for Parkinson's disease (PD). Communication between the gut and brain and immune dysregulation are increasingly being implicated in neurodegenerative disorders such as PD. Here, we show that flies lacking the Gba1b gene, the main fly orthologue of GBA1 , display widespread NF -k B signalling activation, including gut inflammation, and brain glial activation. We also demonstrate intestinal autophagic defects, gut dysfunction, and microbiome dysbiosis. Remarkably, modulating the microbiome of Gba1b knockout flies, by raising them under germ-free conditions, partially ameliorates lifespan, locomotor and immune phenotypes. Moreover, we show that modulation of the immune deficiency (IMD) pathway is detrimental to the survival of Gba1 deficient flies. We also reveal that direct stimulation of autophagy by rapamycin treatment achieves similar benefits to germ-free conditions independent of gut bacterial load. Consistent with this, we show that pharmacologically blocking autophagosomal-lysosomal fusion, mimicking the autophagy defects of Gba1 depleted cells, is sufficient to stimulate intestinal immune activation. Overall, our data elucidate a mechanism whereby an altered microbiome, coupled with defects in autophagy, drive chronic activation of NF -k B signaling in a Gba1 loss-of-function model. It also highlights that elimination of the microbiota or stimulation of autophagy to remove immune mediators, rather than prolonged immunosuppression, may represent effective therapeutic avenues for GBA1- associated disorders. Alterations in gut microbes are increasingly being linked to neurodegenerative disorders such as Parkinson's disease (PD). Mutations in the GBA1 gene cause Gaucher disease (GD), and are the greatest genetic risk factor for PD. Here we show that Drosophila models lacking the fly orthologue of GBA1 ( Gba1b ) have an altered gut microbiome, which triggers a widespread innate immune response. Accordingly, we show that removal of gut bacteria using antibiotics leads to a reduction in the immune response and health benefits. Stimulating innate immunity, specifically the NF- k B/IMD pathway, shortens the survival of Gba1b deficient flies, suggesting that the overactive immune system is toxic. Conversely, genetic removal of this branch of the immune response is harmful and associated with increased gut bacteria. Lastly, we identify widespread defects in a process called autophagy, which helps degrade and recycle cellular waste. Pharmacologically boosting autophagy extends survival and lowers the gut immune response without changing the gut bacteria. Taken together, our findings suggest that the gut microbiome and autophagy defects in Gba1b deficient flies trigger an abnormal immune response. Thus, drugs which alter the gut microbiome or stimulate autophagy may offer potential therapeutic benefits to patients with GBA1- associated disorders.

An altered microbiome in a Parkinson's disease model Drosophila melanogaster has a negative effect on development

The impact of Parkinson's disease-associated gut microbiota on the transcriptome in Drosophila

Oral, Nasal, and Gut Microbiota in Parkinson's Disease.

Drosophila Model for Studying Gut Microbiota in Behaviors and Neurodegenerative Diseases

Autophagic dysfunction and gut microbiota dysbiosis cause chronic immune activation in a Drosophila model of Gaucher disease

Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease

Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease

Lactobacillus probiotics improved the gut microbiota profile of a Drosophila melanogaster Alzheimer's disease model and alleviated neurodegeneration in the eye.

Fecal microbiota from patients with Parkinson's disease intensifies inflammation and neurodegeneration in A53T mice

EGCG ameliorates neuronal and behavioral defects by remodeling gut microbiota and TotM expression in Drosophila models of Parkinson’s disease

[Study of Parkinson's Disease Based on Drosophila Model].

Gut microbiota from patients with Parkinson's disease causes motor deficits in honeybees

Oral and gut dysbiosis leads to functional alterations in Parkinson's disease

Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features

Associations Between Gut Microbiota and Parkinson Disease: A Bidirectional Mendelian Randomization Analysis

Alteration of the fecal microbiota in Chinese patients with Parkinson's disease

Gut Microbiota-Induced Modulation of the Central Nervous System Function in Parkinson's Disease Through the Gut-Brain Axis and Short-Chain Fatty Acids

Compositional changes in fecal microbiota in a new Parkinson's disease model: C57BL/6-Tg(NSE-haSyn) mice

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease

A gut microbial factor modulates locomotor behaviour in Drosophila

Exploring the Alteration of Gut Microbiota and Brain Function in Gender-Specific Parkinson's Disease Based on Metagenomic Sequencing